Cyclophilin A expression and its prognostic significance in lung adenocarcinoma
Cyclophilin A expression and its prognostic significance in lung adenocarcinoma
复制标题
DOI：
10.1111/pin.12593
复制
发表时间：
2017-11-01
影响因子：
2.2
通讯作者：
Noguchi, Masayuki
中科院分区：
文献类型：
--
作者：
Nakano, Noriyuki;Sakashita, Shingo;Noguchi, Masayuki
据报道，亲环蛋白 A (CypA) 在恶性肿瘤中表达上调。 CypA 表达被认为与肿瘤生长和抗凋亡功能的获得有关。尽管 CypA 在肺腺癌中表达上调，但其临床病理意义和在恶性进展中的作用仍不清楚。在这里，我们研究了 CypA 表达对肺腺癌患者预后的影响。选取198例肺腺癌标本，根据世界卫生组织分类（第4版）和Noguchi分类进行重新分类。通过免疫组织化学评估CypA表达，并根据强度和比例计算H分数。通过Western印迹证实所用抗体的特异性，并根据ROC曲线确定截止点。 67例（33.8%）CypA低表达（CypA-L组），131例（66.2%）CypA高表达（CypA-H组）。许多原位腺癌属于CypA-L，晚期腺癌往往被归类为CypA-H。临床上，CypA-H肿瘤患者的预后明显较差于CypA-L肿瘤患者。这是首次研究 CypA 表达水平对切除肺腺癌临床特征的影响。
Cyclophilin A (CypA) has been reported to be upregulated in malignant tumors. CypA expression is thought to be associated with acquisition of tumor growth and anti-apoptotic function. Although upregulation of CypA has been reported in lung adenocarcinoma, its clinicopathological significance and roles in malignant progression remain unclear. Here we investigated the implications of CypA expression for outcome in patients with lung adenocarcinoma. Lung adenocarcinoma specimens from 198 cases were selected and reclassified according to the World Health Organization classification (4th edition) and the Noguchi classification. CypA expression was assessed by immunohistochemistry, and the H-score was calculated on the basis of intensity and proportion. The specificity of the antibody used was confirmed by Western blotting and the cut-off point was determined from the ROC curve. Sixty-seven cases (33.8%) had low CypA expression (CypA-L group) and 131 (66.2%) had high CypA expression (CypA-H group). Many cases of adenocarcinoma in situ were CypA-L, and advanced adenocarcinomas tended to be classified as CypA-H. Clinically, patients with CypA-H tumors showed a significantly poorer prognosis than those with CypA-L tumors. This is the first investigation of the implications of the CypA expression level in terms of the clinical characteristics of resected lung adenocarcinomas.